Residual Risk Prevention In A Special Population: The Diabetic Patient

Residual Risk Prevention in a Special
Population: The Diabetic Patient
Rafael Carmena, MD, PhD
Universidad de Valencia Spain

Rafael Carmena (SPA)
Residual risk prevention in a specialpopulation: the diabetic patient

The content of this presentation represents the independent opinion of the presenter
and do not necessarily represent Pfizer’s opinion. Pfizer is not responsible andshould
not be considered as responsible for its content. These materials have been prepared
with the intention to promote Continued Medical Education

Rafael Carmena (SPA)
Residual risk preventionin a special population: the diabetic patient

EL Contenido de las presentaciones incluidas representan la opinión independiente
de los ponentes y no necesariamente la opinión de Pfizer. Pfizer nose responsabiliza
y no debe ser considerado responsable por el contenido presentado. Estos materiales
se elaboraron con la intención de fomentar la educación médica continua.

A growing burden ofdiabetes,
particularly in developing countries.

LA DIABETES ES UNA ENFERMEDAD CARDIOVASCULAR

Numbers of adults with diabetes in developed and developing countries in 2010 & 2030, according toage group.

Shaw JE et al. Diab Res Clin Practice 2010; 87: 4-14

• Residual risk is defined as the cardiovascular
risk which remains despite having achieved
current standards of care for majorrisk factors.
RR is an important feature in type 2 diabetic
subjects.
• Residual cardiovascular risk is multifactorial
and is made up of two major groups of risk
factors: i.e., those which aremodifiable, such
as dyslipidemia and hypertension, and those
which are not, such as age and gender.

Two important components of the
Residual Risk in diabetic subjects

Dyslipidemia
Type 2Diabetes Mellitus

Hypertension

DIABETIC DYSLIPIDEMIA
(Atherogenic mixed dyslipidemia)
INSULIN RESISTANCE
Cardioprotective
HDL / Apo AI
Atherogenic
ApoB-containing LPs
• VLDL
• IDL
•...